← Back to Clinical Trials
Recruiting NCT06756607

NCT06756607 The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06756607
Status Recruiting
Phase
Sponsor Eastern Cooperative Oncology Group
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2025-04-25
Primary Completion 2028-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
SUPPORT toolkit

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 500 participants in total. It began in 2025-04-25 with a primary completion date of 2028-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to conduct a Hybrid Type 1 cluster-randomized, roll-out effectiveness-implementation trial in NCORP community oncology practice sites (N= 500 Black and Latino cancer patients) to evaluate the effectiveness of the EA SUPPORT intervention combining CT navigators and CT research literacy tools in improving Black and Latino patient referral and accrual to NCI-supported CTs (primary outcomes) and participant and provider awareness and knowledge of CTs (secondary outcomes) while assessing implementation factors. Also, with the CUSP2CT data, Evaluation, and Coordinating Center, conduct final site evaluation and disseminate the SUPPORT intervention to NCORP community oncology sites, research bases, and affiliated trial networks.

Eligibility Criteria

Inclusion Criteria: Participant must be ≥ 18 years of age. Participant must self-identify as Black and/or Latino. Participant must be an oncology patient at a participating NCORP. Participant must be eligible to participate in an ECOG-ACRIN clinical trial. Participant must have the ability to understand and the willingness to sign a e-consent document. Participant must be receiving care at a participating NCORP affiliated community oncology site. Participant must be English or Spanish speaking to be eligible. Participant must have access to a landline, smartphone, computer, or tablet. Exclusion Criteria: \-

Contact & Investigator

Central Contact

Melissa A Simon, MD, MPH

✉ m-simon2@northwestern.edu

📞 (312) 503-8780

Principal Investigator

Melissa A Simon, MD, MPH

STUDY CHAIR

Eastern Cooperative Oncology Group

Frequently Asked Questions

Who can join the NCT06756607 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06756607 currently recruiting?

Yes, NCT06756607 is actively recruiting participants. Contact the research team at m-simon2@northwestern.edu for enrollment information.

Where is the NCT06756607 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT06756607 clinical trial?

NCT06756607 is sponsored by Eastern Cooperative Oncology Group. The principal investigator is Melissa A Simon, MD, MPH at Eastern Cooperative Oncology Group. The trial plans to enroll 500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology